Novel arylpyridine-based 1,3,4-oxadiazoles: Synthesis, antibacterial, and anti-inflammatory evaluation

In view of developing novel bioactive compounds, a series of 2-(5-[2-methyl-6-arylpyridin-3-yl]-1,3,4-oxadiazol-2-ylthio)-1-arylethanones (6a-n) were designed and synthesized in good yield. Novel compounds were evaluated for their antibacterial and anti-inflammatory activities. All synthesized compounds were screened for their antibacterial activity against Staphylococcus aureus, Bascillus subtilis, Eschericia coli, and Pseudomonas aeruginosa strains. Compounds 6a, 6b, 6c, 6h, and 6i displayed the highest antibacterial activity with minimal inhibitory concentration (MIC) values ranging from 6.25-12.5 mu g/mL in comparison with the standard Ciprofloxacin. The results of anti-inflammatory activity of carrageenan-induced footpad edema assay indicated that tested compounds exhibited remarkable anti-inflammatory activity with percentage of inhibition of 63.9-70.1% (potency 96.8-106.20% of indomethacin activity) after 3 hr. Particularly, 6c-e and 6j-l were found to be excellent inhibitors of inflammation, with potential higher than that of the standard, Indomethacin.